Pharmaceutical Care in Viral Diseases (HIV and Hepatitis C)
- 828 Downloads
Pharmacists are well positioned within the care continuum to help patients achieve their treatment outcomes as they are easily accessible, are in contact with the patients when they visit the pharmacy at treatment initiation and overtime for refill visits, and they have education and training in the management of drug–drug interactions and adverse effects. In this chapter, we highlighted evidence-based pharmaceutical care interventions in adherence, which is an important DRP in HIV and hepatitis C infections.
KeywordsPharmaceutical Care AIDS Hepatitis Prevention Medication adherence
- 1.HIV/AIDS JUNPo. Global AIDS update 2016. Geneva: UNAIDS;2016.Google Scholar
- 2.Organization WH. Global hepatitis report 2017: executive summary;2017.Google Scholar
- 5.IDSA Aa. HCV Guidance: recommendations for testing, managing, and treating Hepatitis C [Available from: https://www.hcvguidelines.org/evaluate/when-whom.
- 6.EACS. European treatment guidelines [Available from: http://www.eacsociety.org.
- 7.Liver SAftsot. SASL-SSI Expert opinion statement on the treatment of Chronic Hepatitis C—August 2017 Update [Available from: https://sasl.unibas.ch/6SASLguidelines.php.
- 8.Liverpool Uo. HIV Drug interaction checker [Available from: http://www.hiv-druginteractions.org/.
- 9.Liverpool Uo. [Available from: http://www.hep-druginteractions.org/.
- 19.Belperio PS, Backus LI, Ross D, Neuhauser MM, Mole LA. A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system. J Manag Care Pharm. 2014;20(6):533–40.Google Scholar
- 21.Kamal S, Glass TR, Calmy A, Lecompte MT, Bugnon O, Parienti J-J, et al. 145-Does an adherence-enhancing program increase retention in care in the Swiss HIV Cohort? IAPAC; 06.06.2017; Miami, USA;2017.Google Scholar